Biocryst Pharmaceuticals (BCRX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Biocryst Pharmaceuticals (BCRX) do?
Biocryst Pharmaceuticals Inc (BCRX) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells Orladeyo, an oral daily pill that prevents attacks of hereditary angioedema. Develops and commercializes other targeted enzyme inhibitors for rare complement system disorders. BioCryst designs and commercializes oral small molecule medicines for rare genetic and enzyme mediated diseases. It is worth $1.88B on the market and sold $960.93M over the last year.
- Market cap
- $1.88B
- P/E ratio
- None (reported a loss)
- Annual sales
- $960.93M
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 17, 2026
Brands and businesses behind BCRX
- Orladeyo: A daily prescription capsule that prevents hereditary angioedema attacks, earning revenue through specialty pharmacy sales.
- Rapivab: An emergency intravenous influenza treatment sold to hospitals and government stockpiles.
BCRX’s flags, in plain English
Each flag is a number from Biocryst Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Wide Gross Margin
Gross margin of 97.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 117.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Cheap on Cash Flow
Priced at 5.4 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Burning Cash
Losing money, profit margin of -37.4%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about BCRX
How big is Biocryst Pharmaceuticals?
Biocryst Pharmaceuticals’ market cap is $1.88B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $960.93M: what customers paid the company over the last year, before any costs.
What is BCRX’s P/E ratio?
BCRX has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with BCRX?
Revenue depends almost entirely on a single commercial drug, making cash flow vulnerable to rival treatments. That is one risk on Biocryst Pharmaceuticals’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Biocryst Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BCRX’s filings on SEC.gov. The Margin Monkey is research, not advice.
